2015
DOI: 10.1038/nrclinonc.2015.61
|View full text |Cite
|
Sign up to set email alerts
|

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

Abstract: During the past decade, cancer stem cells (CSCs) have been increasingly identified in many malignancies. Although the origin and plasticity of these cells remain controversial, tumour heterogeneity and the presence of small populations of cells with stem-like characteristics is established in most malignancies. CSCs display many features of embryonic or tissue stem cells, and typically demonstrate persistent activation of one or more highly conserved signal transduction pathways involved in development and tis… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

8
923
0
11

Year Published

2017
2017
2022
2022

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 1,067 publications
(988 citation statements)
references
References 174 publications
8
923
0
11
Order By: Relevance
“…Current pharmacological therapies targeting Wnt signaling are still in their infancy 148. Indeed, several pharmaceutical molecules that are known to modulate the Wnt signaling pathway have been developed and tested in cancer and neurologic disorder therapy 149, 150. A couple of others are used in the treatment of osteoporosis 151.…”
Section: Resultsmentioning
confidence: 99%
“…Current pharmacological therapies targeting Wnt signaling are still in their infancy 148. Indeed, several pharmaceutical molecules that are known to modulate the Wnt signaling pathway have been developed and tested in cancer and neurologic disorder therapy 149, 150. A couple of others are used in the treatment of osteoporosis 151.…”
Section: Resultsmentioning
confidence: 99%
“…Currently PF-03084014 is in phase I or phase II trials for the treatment of T-ALL, lymphoma, desmoid tumors, and fibromatosis (4,20,21). Although abnormal expression of the Notch pathway has been demonstrated in hepatocellular carcinoma (22), there is no reported study on the anticancer potential of Notch inhibitors on hepatocellular carcinoma from the cellular level to animal models in vivo.…”
Section: Introductionmentioning
confidence: 98%
“…Therefore, these developmental pathways may be important therapeutic targets for the suppression of CSC self-renewal, proliferation, and tumor progression (4). Over the past few years, new investigational agents have been developed to target CSCs by inhibiting the Notch pathway, although robust antitumor activity has not yet been observed in clinical trials (4).…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations